The route to financial sustainability of a large Public Private Partnership – the example of the clinical trial network conect4children (c4c)

Publications

The Innovative Medicines Initiative (IMI), now the Innovative Health Initiative (IHI), funds promising projects across Europe to turn health research into real benefits for patients and society. However, many of these initiatives struggle to maintain impact once EU funding ends. Despite general recognition of the need for financial and organisational sustainability, there is a lack…

Developing and streamlining clinical trial services to support pediatric drug development across 21 countries in Europe: insights from the conect4children (c4c) network

Publications

The success of multinational pediatric clinical trials depends on efficient, high-quality, and scalable trial support services. From 2018 to 2025, the conect4children (c4c) network – a public-private partnership funded by the Innovative Medicines Initiative 2 – brought together 10 pharmaceutical companies and 33 academic and third-sector organizations to develop such services across 220+ sites in…

The Potential to Leverage Real-World Data for Pediatric Clinical Trials: A Proof-of-Concept Study

News, Publications

Pediatric clinical research, especially in rare diseases, faces persistent challenges including the identification and recruitment of eligible patients, assessing protocol feasibility, and ensuring efficient trial execution. These issues are compounded by small, age-stratified populations and fragmented clinical data. Real-world data (RWD), especially when drawn from electronic health records (EHRs), present an opportunity to support innovative…

GLOPAD Paediatric Use Case: Important Considerations in Assessing the Population Representativeness of Paediatric Clinical Trials

News, Publications

Randomized controlled trials remain the gold standards for generating new novel medical evidence. To be meaningful the evidence generated must be generalizable to the real-world population. The generalisability of a trial is partially determined by its population representativeness, which measures the coverage of the trial participants within the real-world patient population.